Pituitary Adenoma and Serum Lipid

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-01

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pituitary adenomas are usually benign monoclonal neoplasms caused by a mixture of pituicyte alterations together with a changed endocrine and paracrine regulatory milieu. Thus, it can cause serious health problems such as abnormal target organ function, pain, disability and even death. In clinical practice, we found many patients with pituitary adenomas are usually accompanied by hyperlipidemia, which is the main cause of cardiovascular diseases. However, it has been unclear if there is an association between pituitary adenomas and serum lipid profile. In the present study, we aim to focus on the patients with pituitary adenomas and their lipid profile before and after operation including first occurrence and recurrence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Growth Hormone Therapy on Metabolic Function in Fatty Liver Post-Pituitary Adenoma Surgery

NCT06448195

Growth Hormone Treatment

RECRUITING PHASE4

Setting Benchmarks for Transsphenoidal Resection of Pituitary Adenomas

NCT04951557

Pituitary Adenoma Pituitary Tumor Pituitary Diseases

UNKNOWN

Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly

NCT00921609

Acromegaly

ACTIVE_NOT_RECRUITING

Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.

NCT02092129

Acromegaly Surgery

UNKNOWN

Lipolytic Effects of GH in Hypopituitary Patients in Vivo

NCT02782208

Hypopituitarism Insulin Resistance Endocrine System Diseases +4 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pituitary Adenoma 1, Acth-Secreting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with pituitary adenomas resection

Patients suffers from pituitary adenomas and undergo transsphenoidal surgery for at least once

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients diagnosed with pituitary adenomas
2. All adenomas were resected by transsphenoidal surgery and identified by histological diagnoses.

Exclusion Criteria

1. Missing vital data, such as age, gender, serum lipid profile, pathology reports;
2. Complications or conditions that affect pituitary status and lipid metabolism, such as pregnancy, malignant adenomas or severe hepatic or renal dysfunction and
3. Use of any medication that affects the pituitary or lipid metabolism, including statins, fibrates, thyroid hormones, anti-thyroid drugs, iodine, amiodarone, alemtuzumab, lithium, tyrosine kinase inhibitors, interferon, estrogens, androgens,glucocorticoids, nonsteroidal anti-inflammatory drugs, antiepileptic drugs, rifampicin, furosemide, heparin or β-adrenoceptor blockers in the past 3 months.

Eligible Sex

ALL

Accepts Healthy Volunteers

No